Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDER’s Drug Integrity Program Gains Formal Role In Compliance Office Reorg

Executive Summary

FDA’s nascent Drug Integrity and Security Program gains an enhanced and more formal role with the reorganization and elevation of the Center for Drug Evaluation and Research’s Office of Compliance to “super-office” status.
Advertisement

Related Content

CDER’s New Compliance Director Sklamberg Brings Experience On Compounding Issues
Generic Drugs Gain Status Boost Within CDER
FDA's Office of Medical Policy Grows Into A "Super Office"; DDMAC Gets A Promotion
FDA Reorganization Adds "Directorate" Layer, But Sharpens Agency's Focus
FDA Becomes An Agency Of “Directorates” Under Hamburg’s Reorganization
FDA Reorganization Adds "Directorate" Layer, But Sharpens Agency's Focus
CDER’s New “Super-Office” Of Compliance
CDER's Newest "Super-Office" Focuses On Drug Security
In Brief
CDER Reorganization Creates Drug Safety “Super-Office”; Management Support Is Goal

Topics

Advertisement
UsernamePublicRestriction

Register

PS053480

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel